What Atossa Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 9 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 210,222 |
| Disposed | 0 | 0 |
| Net activity | +0 | +210,222 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Finn Jonathan | Director | May 12 | Grant / award · A | +10,000 | — | — | 11,666 |
| Galli Stephen J | Director | May 12 | Grant / award · A | +10,000 | — | — | 10,006 |
| Chen Shu-Chih | Director | May 12 | Grant / award · A | +10,000 | — | — | 10,000 |
| Remmel H. Lawrence | Director | May 12 | Grant / award · A | +10,000 | — | — | 10,683 |
| Cigler Tessa | Director | May 12 | Grant / award · A | +10,000 | — | — | 10,000 |
| Steinhart Richard I | Director | May 12 | Grant / award · A | +10,000 | — | — | 10,000 |
| Quay Steven C | President & CEO | Mar 27 | Grant / award · A | +65,000 | — | — | 88,038 |
| Daniel Mark James | Chief Financial Officer | Mar 26 | Grant / award · A | +63,000 | — | — | 63,000 |
| Quay Steven C | President & CEO | Jan 20 | Grant / award · A | +331,674 | — | — | 345,572 |
| Quay Steven C | President & CEO | May 21 | Open-market buy · P | +11,239 | $0.88 | +$9.89K | 13,898 |
| Remmel H. Lawrence | Director | Mar 26 | Open-market buy · P | +10,000 | $0.70 | +$7K | 10,257 |
| Finn Jonathan | Director | Apr 10 | Open-market buy · P | +25,000 | $1.77 | +$44.3K | 25,000 |
| Weaver Gregory L | Former EVP, CFO, & Director | Nov 15 | Open-market sale · S | −50,000 | $0.65 | −$32.5K | 55 |
| Weaver Gregory L | EVP & CFO | Jun 20 | Open-market buy · P | +50,000 | $0.97 | +$48.5K | 50,055 |
| Weaver Gregory L | Director | Jul 02 | Open-market sale · S | −107,497 | $5.58 | −$600K | 0 |
| Weaver Gregory L | Director | Jul 02 | Withheld — tax / exercise cost · F | −57,084 | $6.40 | −$365K | 107,497 |
| Weaver Gregory L | Director | Jul 02 | Exercise / conversion · M | +70,000 | $1.70 | +$119K | 164,581 |
| Weaver Gregory L | Director | Jul 02 | Exercise / conversion · M | +45,000 | $2.52 | +$113K | 94,581 |
| Weaver Gregory L | Director | Jul 02 | Exercise / conversion · M | +45,000 | $2.38 | +$107K | 49,581 |
| Weaver Gregory L | Director | Jul 02 | Exercise / conversion · M | +4,581 | $5.64 | +$25.8K | 4,581 |
Loading...
